Relmada Therapeutics (RLMD) Non-Current Assets (2013 - 2026)
Relmada Therapeutics (RLMD) reported Non-Current Assets of $19500.0 for Q1 2026, down 11.26% year-over-year from $21975.0 in Q1 2025, and little changed on a QoQ basis from $19500.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 14 years of Non-Current Assets data on file, last reported at $19500.0 in Q1 2026.
- Quarterly Non-Current Assets fell 11.26% year-over-year to $19500.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82950.0 (down 30.61% YoY) and the FY2025 annual result came in at $19500.0, down 11.26% from the prior year.
- Non-Current Assets held at $19500.0 in Q1 2026 per RLMD's latest filing, from $19500.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $53625.0 in Q2 2024 and bottomed at $16095.0 in Q3 2022.
- The 5-year median for Non-Current Assets is $28293.0 (2022), against an average of $30613.6.
- The widest annual swing landed in 2022, when Non-Current Assets slumped 68.88%; it then jumped 196.46% in 2023.
- Tracing RLMD's Non-Current Assets over 5 years: stood at $34875.0 in 2022, then advanced by 23.66% to $43125.0 in 2023, then sank by 49.04% to $21975.0 in 2024, then fell by 11.26% to $19500.0 in 2025, then changed by 0.0% to $19500.0 in 2026.
- Per Business Quant, the three latest RLMD Non-Current Assets figures stand at $19500.0 (Q1 2026), $19500.0 (Q4 2025), and $21975.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 19,500.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,500.00 |
| Dec 31, 2025 | 19,500.00 |
| Sep 30, 2025 | 21,975.00 |
| Jun 30, 2025 | 21,975.00 |
| Mar 31, 2025 | 21,975.00 |
| Dec 31, 2024 | 21,975.00 |
| Sep 30, 2024 | 21,975.00 |
| Jun 30, 2024 | 53,625.00 |
| Mar 31, 2024 | 43,125.00 |
| Dec 31, 2023 | 43,125.00 |
| Sep 30, 2023 | 47,715.00 |
| Jun 30, 2023 | 34,590.00 |
| Mar 31, 2023 | 34,875.00 |
| Dec 31, 2022 | 34,875.00 |
| Sep 30, 2022 | 16,095.00 |
| Jun 30, 2022 | 35,238.00 |
| Mar 31, 2022 | 28,293.00 |
| Dec 31, 2021 | 28,293.00 |
| Sep 30, 2021 | 47,275.00 |
| Jun 30, 2021 | 69,090.00 |
| Mar 31, 2021 | 90,906.00 |
| Dec 31, 2020 | 112,635.00 |
| Sep 30, 2020 | 133,949.00 |
| Jun 30, 2020 | 154,870.00 |
| Mar 31, 2020 | 175,552.00 |
| Dec 31, 2019 | 195,844.00 |
| Sep 30, 2019 | 215,793.00 |
| Jun 30, 2019 | 235,352.00 |
| Mar 31, 2019 | 273,427.00 |
| Dec 31, 2018 | 267,207.00 |
| Sep 30, 2018 | 285,848.00 |
| Jun 30, 2018 | 310,112.00 |
| Mar 31, 2018 | 314,681.00 |
| Dec 31, 2017 | 331,897.00 |
| Sep 30, 2017 | 348,429.00 |
| Jun 30, 2017 | 362,006.00 |
| Mar 31, 2017 | 926,828.00 |
| Dec 31, 2016 | 929,676.00 |
| Sep 30, 2016 | 950,627.00 |
| Jun 30, 2016 | 945,703.00 |
| Mar 31, 2016 | 942,432.00 |
| Dec 31, 2015 | 948,526.00 |
| Sep 30, 2015 | 434,153.00 |
| Jun 30, 2015 | 424,736.00 |
| Mar 31, 2015 | 35,448.00 |
| Dec 31, 2014 | 35,610.00 |
| Sep 30, 2014 | 29,017.00 |
| Jun 30, 2014 | 21,941.00 |
| Nov 30, 2013 | 1,400.00 |
| Aug 31, 2013 | 1,550.00 |
| May 31, 2013 | 1,700.00 |